Aug 16 (Reuters) - Seagen said on Wednesday its cancer therapy in combination with Roche's Kadcyla helped control disease progression in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
4,338 INR | +0.78% | +3.03% | 2.38B | ||
2,728 PTS | +0.54% | -0.01% | - | ||
225.1 CHF | +1.26% | +3.59% | 200B | ||
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |